Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab. (Q54660064)
Jump to navigation
Jump to search
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab. |
scientific article |
Statements
Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab. (English)
Allan Lipton
Wolfgang J Köstler
Kim Leitzel
Suhail M Ali
Jeff Sperinde
Jodi Weidler
Agnes Paquet
Thomas Sherwood
Weidong Huang
Michael Bates
Trastuzumab Response Biomarker Group
1 November 2010
116
22
5168-5178
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference